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Emotional Expression During Attention-Deficit/
Hyperactivity Disorders Treatment:
Initial Assessment of Treatment Effects
C.J. Kratochvil, M.D.,1 D. Faries, Ph.D.,2 B. Vaughan, A.P.R.N.,1 A. Perwien, Ph.D.,2
J. Busner, Ph.D.,3 K. Saylor, Ph.D.,4 S. Kaplan, M.D.,3 C. Buermeyer, Ph.D.,4 and
R. Swindle, Ph.D.2

ABSTRACT
Objective: The purpose of this research was to provide an initial examination of the effects of
atomoxetine and stimulants on emotional expression using a newly developed scale for
assessing emotional expression in children with attention-deficit/hyperactivity disorder
(ADHD).
Method: The parent-rated Expression and Emotion Scale for Children (EESC) was collected
during two studies. During a cross-sectional validation study, the EESC was completed to assess
the child’s current treatment and retrospectively for previous medication. In a randomized,
placebo-controlled trial of atomoxetine, the EESC was collected at baseline and endpoint.
Results: In the validation study, no statistically significant differences in EESC scores were
found between groups taking atomoxetine (n 5 74) and stimulants (n 5 105). Patients who
switched from a stimulant to atomoxetine (n 5 40) had greater improvement in emotional
expression than those switched to another stimulant (n 5 21) (p 5 0.008). In the clinical trial,
no difference in rates of worsening of emotional expression were observed (atomoxetine
8.8%, placebo 12.3%; p 5 0.440).
Conclusion: No treatment differences in emotional expression were observed based on current medications. However, stimulant patients needing to switch medications may have
greater improvements in emotional expression by switching to atomoxetine.

expression as potential treatment-emergent
effects have been rare. This may be attributed
to a general lack of data on the tolerability of
pediatric pharmacotherapies, or to the lack of
validated instruments for measuring emotional expression. One notable experimental
study demonstrating negative emotional side
effects of stimulant medication is Whalen et al.’s

INTRODUCTION

A

LTHOUGH RESEARCH HAS DOCUMENTED the efficacy of treatments on the core symptoms
of attention-deficit/hyperactivity disorder
(ADHD) and the common physical side effects
of medications used to treat it (AACAP 2002),
quantitative evaluations of changes in emotional
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(1989) cross-over demonstration of observable
“dysphoria” induced by methylphenidate
(MPH). In a pair of blinded placebo-drug crossover designs, they used an observer rating
measure in a laboratory group game task. The
rating items comprising the dysphoria rating
measure were “Withdrawn, hanging back,”
“Sad or unhappy,” and “Flat or unemotional.”
In both studies, children on MPH during the
task were rated significantly more dysphoric
than on days when they were on placebo.
Some clinicians who use medication to treat
ADHD in children have experienced a parent
saying “I don’t want to make my child a zombie.” Clinicians have also seen personality
changes in certain children treated with
ADHD pharmacotherapy. Employing the construct of “negative emotional expression,” including affective blunting, mood lability, and
the “zombie effect,” a new parent-reported
scale has been developed in an attempt to
quantify the impact of medication on emotional expression in children: The Expression
and Emotion Scale for Children (EESC).
EESC development
Development of the EESC followed the
guidelines outlined by DeVillis (1991): Definition and refinement of the construct to be measured, generation of an item pool, examination
of understandability and appropriateness of
the items and response choices, and determination of the psychometric properties of the
measure. Qualitative research methods, including focus groups and cognitive interviews, were used to refine the construct and
develop an initial item pool. On the basis of information collected from the focus groups, and
the input of clinician investigators with expertise in ADHD, an initial 37-item scale was
developed. Cognitive interviews were then
conducted to examine the understandability
and appropriateness of the items and response
choices on the scale.
The product of these initial qualitative
phases was the EESC Version 1, a 29-item scale
designed to assess the impact of pharmacotherapy on emotional expression in children
treated for ADHD (Kratochvil et al. 2004).
Each item of the EESC is rated on a 5-point
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scale (1 5 ‘Not true at all’, 2 5 ‘A little true’, 3
5 ‘Somewhat true’, 4 5 ‘Pretty much true’, 5 5
‘Very much true’). Of the 29 items, 14 addressed positive aspects of emotional expression (“My child seems happy.”), with the
remaining 15 concentrating on negative qualities (“My child zones out.”). The scale items
asked parents to rate the child’s mood, emotional state, and personality characteristics
considering the past 2 weeks. For scoring the
EESC, the positive items scores were transformed such that higher scores represent
‘worse’ symptoms for all items and subscales.
Specifically, for positive items, the score analyzed for each item was ‘6 – raw score’. Total
and subscale scores were then computed as
the sum of the (transformed) item scores. Maximum likelihood factor analysis with varimax
orthogonal rotation was used to identify three
potential subscales of the EESC: A 13-item positive emotions subscale, a 10-item emotional
flatness subscale, and a 5-item emotional lability
subscale.
Details of the development process and a full
assessment of the basic psychometric properties
from the validation study have been documented in a separate report (Perwien et al.,
submitted). In brief, the validation study confirmed that the EESC total score and its subscales have adequate psychometric properties,
although minor modifications to the scale
were recommended (see Appendix). Adequate
internal consistency was observed (Cronbach’s
alpha of 0.91 for the total, 0.87 for positive, 0.90
for flat, 0.86 emotional lability subscales). Convergent and divergent validity were established
using multiple scales and test-retest reliability
was found to range from 0.65 to 0.69 (intraclass
correlation coefficients). The recommended
modifications were to improve the floor effects
of the flat subscale. However, initial testing of
the new items (with improvements in floor
effects) in a subset of patients demonstrated a
high correlation (r 5 0.92) with the original
items. Thus, the analysis here focuses on the full
set of patients with the original items.
Objectives
The objective of the research presented
here was to employ the EESC for an initial
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examination of the effects of atomoxetine and
stimulants on emotional expression. Data from
both the validation study and a randomized
clinical trial were used. The validation study
includes cross-sectional data from parents of
children with ADHD treated with either atomoxetine or a stimulant. This allows for a comparison of treatment groups on the basis of
naturalistic selection of treatments. This study
also collected retrospective data from past
treatments, providing an opportunity for preliminary assessment of reported changes in
emotional expression as children change treatments. Data from the randomized, doubleblind clinical trial allowed a prospective
assessment of changes in emotional expression
over time for patients starting treatment with
atomoxetine as compared to placebo.
METHODS
Validation study
The EESC validation study was conducted at
three experienced ADHD research sites in
Pennsylvania, Maryland, and Nebraska, This
study included 179 parents/guardians (hereafter referred to as parents) and their 6 to 12year-old children with ADHD who were taking
either atomoxetine or stimulant medication.
The goals of this study were to examine the
psychometric properties of the scale and make
any necessary modifications. Parents of children with a diagnosis of ADHD were recruited
from the community by print advertisements,
letters to community clinicians, and from the
investigators’ own practices. Parents and children had to possess an appropriate level of
cognitive skills so that they could communicate suitably with investigators. Per entry criteria, the child’s ADHD must have been
diagnosed by an M.D. or Ph.D. trained in the
assessment of pediatric mental health disorders, and the child must have been on a single
pharmacotherapy treatment for ADHD, either
atomoxetine or a stimulant. The children could
not be on any other concurrent psychotropic
medication. In addition, the current ADHD
treatment must have been stable, that is, no
recent changes in medication or dose of medication for a minimum of 2 weeks.
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Each parent–child dyad attended a single
clinic visit at their participating site. After informed consent was obtained from the parent
and written assent was obtained from the
child, the parent provided demographic and
family information, as well as the child’s medication history, including rationale for prior
medication changes. Parents then completed
the EESC scale for their child on the basis of
his or her current treatment. If the child had
switched medications in the recent past, a retrospective EESC based on the child’s most recent previous ADHD medication was also
completed. A subset of parents completed a
follow-up EESC approximately 2 weeks later
to allow for test–retest reliability assessment.
The computer-based Diagnostic Interview for
Children and Adolescents-IV (DICA-IV; Reich
et al. 1997) was completed by the parent to assess co-morbid disorders. A positive diagnosis
of ADHD based on the DICA-IV was not
required for study participation. Other measures included the Conners’ Parent Rating
Scale—Revised: short form (CPRS-R:S; Conners 1997), The Child Behavior Checklist
(CBCL; Achenbach 1991; Achenbach and
Rescorla 2001), and the child-rated Child Depression Inventory (CDI; Knight et al. 1988; Kovacs 1992), and Multidimensional Anxiety
Scale for Children; (MASC; March et al. 1997)
were also collected at the initial time point.
Clinical trial
The EESC scale was included as part of a
battery of measurements at 9 of 14 sites in a
randomized, double-blind, atomoxetine clinical
trial. In this trial, 288 (208 from sites where the
EESC was collected) 6 to 12-year-old children
with a Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, text revision
(DSM-IV-TR; American Psychiatric Association 2000) diagnosis of ADHD were randomized to either atomoxetine morning dosing,
atomoxetine evening dosing, or placebo for
approximately 6 weeks of double-blind treatment. The ADHD diagnosis was established at
study entry using the Kiddie Schedule for Affective Disorders and Schizophrenia for School
Aged Children–Present and Lifetime, Behavioral Disorders Supplement (K-SADS-PL: Beh)
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module criteria for ADHD (Kaufman et al. 1997).
The K-SADS-PL:Beh was administered by a
trained and approved researcher at each site.
Patients were required to score at least 1.5
standard deviations (SD) above the age/gender norm for their ADHD diagnostic subtype
on the ADHD Rating Scale–Parent Version, Investigator Scored (DuPaul 1991; Faries et al.
2001). A medication washout of 5 half-lives
prior to randomization to treatment was required for children who were taking medication at the time of study entry. Use of other
psychotropic medications or psychoactive substances during the course of the study was not
permitted. EESC data were collected at baseline
(randomization visit) and treatment end point
(6 weeks or early discontinuation). Collection of
the EESC data was a secondary objective of the
trial. The primary purpose was to gather data to
assess the relative efficacy and safety of morning and evening dosing of atomoxetine.
Statistical methods
Analysis of variance (ANOVA) was used to
test the null hypothesis of no group (treatment) differences in EESC scores in both the
validation study and clinical trial data.
ANOVA models for the clinical trial data
analysis included terms for investigational
site, treatment group, and baseline score.
ANOVA models from the validation study included investigational site, age, gender, race,
treatment group, co-morbid diagnoses, such as
oppositional defiant disorder (ODD), conduct
disorder (CD), enuresis, encopresis, dysthymia, depression, and baseline score (when
change scores were the outcome variable). The
inclusion of additional covariates was important in the analyses of the Validation study as
group comparisons from this study are based
on naturalistically selected and not randomly
formed treatment groups. Thus, the covariates
serve as a potential adjustment for selection
bias. As a sensitivity analysis, disease severity
measures (ADHD, depression, anxiety) were
also added to the validation study models as
covariates. The results of the sensitivity analyses were consistent and are not reported here.
Categorical changes in EESC scores in the
randomized clinical trial were also assessed
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using chi-square tests. Changes were categorized based on whether they were less than or
at least 1 standard error of the mean (SEM).
Changes of at least 1 SEM have been previously utilized as a measure of meaningful
change (Wyrwich et al. 1999).
Two-sided, 0.05 significance levels were
used for all statistical tests. All statistical analyses were performed using SAS (1999).
RESULTS
Baseline patient characteristics
Tables 1 and 2 summarize the patient characteristics for participants in the validation
study and clinical trial, respectively. Patient
characteristics are provided by current (ongoing) treatment group in the validation study
and by the randomized treatment group in the
clinical trial. The clinical trial population was
less advanced in grade level, with a slightly
higher percentage of males. Differences in
rates of co-morbid diagnoses may be due in
part to the different diagnostic tools–as the
DICA is only used to suggest provisional diagnoses that would then need examination by a
physician to either confirm or refute the diagnoses. Overall, the samples appeared to be reasonably representative of the general ADHD
population, predominantly male, combined
subtype, and often presenting with a co-morbid
diagnosis.
In the randomized clinical trial, the atomoxetine and placebo treatment groups had similar patient characteristics. In the validation
study where treatment with atomoxetine or a
stimulant was determined by choice, some differences were noted. Specifically, patients taking atomoxetine tended to be older, less likely
to be Caucasian, more likely to have co-morbid
depression, and had slightly less severe
ADHD symptoms than patients taking stimulants. In addition, the groups had different
treatment histories, with almost two thirds of
the atomoxetine patients having tried a stimulant in the past but only 20% of stimulant
patients having tried atomoxetine in the past.
This discrepancy was likely due to the relatively recent availability of atomoxetine at the
time of the study.
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TABLE 1. SUMMARY OF PATIENT CHARACTERISTICS–VALIDATION STUDY

n
Age, mean (SD)
Grade, mean (SD)
Male (%)
Race (% Caucasian)
Spec education service use (%)
Most recent prior treatment (%)
Atomoxetine
Stimulants
None
CPRS ADHD Index, mean (SD)
MASC Total, mean (SD)
CDI Total, mean (SD)
CBCL Total, mean (SD)
Co-morbid diagnosesb
ODD
Phobias
Enuresis
Conduct disorder
Major depression

Atomoxetine

Stimulants

74
9.8 (1.8)
4.6 (1.9)
67.6
67.6
49.3

105
9.1 (1.8)
4.0 (2.0)
65.7
81.0
36.1

0.0
63.0
37.0
63.7 (13.3)
50.4 (9.4)
49.5 (8.4)
59.4 (10.8)

20.0
44.8
35.2
67.8 (12.3)
52.2 (9.4)
47.6 (9.4)
62.3 (10.5)

44.1
19.1
17.7
10.3
7.4

38.4
14.1
9.1
9.1
0.0

Test stata

p value

2.56
2.11
0.07
4.19
2.89

0.011
0.037
0.780
0.041
0.089

22.10
21.25
1.41
21.84

0.037
0.207
0.159
0.068

0.55
0.74
2.68
0.07
7.50

0.459
0.391
0.101
0.795
0.006

SD 5 standard deviation; CPRS 5 Conners’ parent rating scale; ADHD 5 attention-deficit/hyperactivity disorder;
MASC 5 multidimensional anxiety scale for children; CDI 5 child depression inventory; CBCL 5 child behavior
checklist; ODD 5 oppositional defiant disorder; DICA-IV 5 diagnostic interview for children and Adolescents-IV; df
5 degrees of freedom.
a
Test statistics were t-statistics for continuous measures (with df ranging from 142 for the MASC, 163 for CDI, 175
for CBCL, and 177 for age, grade, and CPRS due to missing data) and chi-square statistics (1 df) for binary variables.
b
Diagnosis suggested by DICA-IV.

TABLE 2. SUMMARY OF PATIENT CHARACTERISTICS–CLINICAL TRIAL

n
Age, mean (SD)
Grade, mean (SD)
Male (%)
Race (% Caucasian)
Prior stimulant treatment (%)
ADHD subtype
Hyperactive/Impulsive
Inattentive
Mixed
CGI–Severity
Co-morbid Diagnosesb
ODD
Conduct disorder
Major depression
Phobias

Atomoxetine

Placebo

Test stata

p value

140
8.8 (1.6)
2.9 (1.6)
77.1
72.9
28.8

68
8.9 (1.7)
3.0 (1.7)
73.5
70.6
41.2

20.13
20.45
0.33
0.12
3.20

0.900
0.656
0.567
0.732
0.074

2.1
23.6
74.3
5.1 (0.8)

4.4
23.5
72.1
5.0 (0.7)

0.84
0.00
0.12
0.20

0.359
0.995
0.732
0.809

31.4
1.4
0
0

38.2
0
0
0

0.95
0.99
—
—

0.330
0.320
—
—

SD 5 standard deviation; ADHD 5 attention-deficit/hyperactivity disorder; CGI-severity 5 Clinical Global
Impressions–severity; ODD 5 oppositional defiant disorder; df 5 degrees of freedom; K-SADS 5 Kiddie Schedule
for Affective Disorders and Schizophrenia for School-Aged Children.
a
Test statistics were t statistics for continuous measures (with df of 199 for the CGI to 206 for age and grade) and
chi-square statistics (1df) for binary variables.
b
Diagnosis confirmed by K-SADS structured diagnostic interview.
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In univariate analyses, EESC scores were not
significantly related to most baseline demographics and co-morbid diagnoses. Exceptions
in the validation study include higher total
scores for patients with phobias, higher emotional lability scores for females and those
with CD, and higher flat subscale scores for
patients with major depressive disorder
(MDD). Exceptions in the clinical trial included higher flat subscale scores for minorities and higher total scores for patients with
oppositional defiant disorder (ODD).
Assessment of treatment effects
Results from three analyses of treatment
differences in EESC scores are presented in the
subsections below: (1) a comparison of EESC
scores between groups formed by naturalistically selected treatment (atomoxetine vs stimulants) in the validation study; (2) a comparison of
changes in EESC scores from previous to current
treatment for patients in the validation study
who switched from stimulants to atomoxetine
versus patients who switched within the stimulant class of medications; and (3) a comparison of
changes in EESC scores from baseline to endpoint (6 weeks) for atomoxetine-versus placebotreated patients in the randomized clinical trial.
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Validation study—cross-sectional analysis:
Figure 1 summarizes the mean scores for the
total score and each of the EESC subscales by
the current treatment, atomoxetine or a stimulant. The ‘stimulant’ group was made up of various treatments, with the most common being
Concerta (43.8%), Adderall (16.2%), Ritalin
(16.2%), and Adderall XR (11.4%). The differences in scores between patients on atomoxetine [total EESC: mean(SD) 59.3 (17.0)] and on
stimulant (total EESC: mean(SD) 60.5 (16.7))
treatment were small and an ANOVA revealed
no statistically significant differences (F[1,138]
5 0.2, p 5 0.624]. There were also no statistically
significant differences between treatment
groups on the three EESC subscale scores.
Further analysis showed no significant
differences between short-(most common:
Adderall, Ritalin) and long-acting stimulants
(most common: Concerta, Adderall XR) [long
acting, n 5 60, mean (SD) 5 60.0 (16.8); short
acting, n 5 36, mean (SD) 5 61.2 (16.9); 9 stimulant patients had missing item scores and
were excluded from analyses of total scores].
In addition, the differences between MPH
medications and amphetamine medications
were not statistically significant [MPH: n 5 62,
mean (SD) 5 58.9 (16.9); amphetamine, n 5 30,
mean (SD) 5 63.6 (16.6); p 5 0.165; 4 stimulant

FIG. 1. EESC mean scores based on current treatment, validation study. Values reports are mean (SD). p Values are
based on F tests from ANOVA with terms for demographics, site, treatment, and co-morbid diagnoses. F statistics
(denominator df) were: Total, 0.2 (138); flat, 0.6 (146); emotion, 1.1 (146); and positive, 0.0 (145). EESC 5 Expression
and emotion scale for children; SD 5 standard deviation; df 5 degrees of freedom; ANOVA 5 analysis of variance.
ATX = atomoxetine; STM = stimulant.
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TABLE 3. CHANGES FROM PAST TO CURRENT TREATMENT EESC TOTAL SCORES–WITHIN GROUP CHANGES: VALIDATION STUDY

Past and Current Treatment

n

Prior
mean (SD)

Atomoxetine to Stimulant
Stimulant to Atomoxetine
Stimulant to Stimulant

18
40
21

67.4 (17.9)
83.4 (24.2)
81.9 (21.5)

Change:
Prior to current
mean (SD)

Test-statistic

Within-group
p value

26.2 (15.1)
221.6 (29.1)
215.1 (18.5)

21.75
24.69
23.75

0.099
,0.001
0.001

All subscales also demonstrated significant improvement from the prior score. Test statistics/p values were based
on paired t-tests. EESC scales for 8 patients were not fully completed and not included in this analysis.
SD 5 standard deviation.

patients were taking modafinil and were
excluded from this analysis].
The overall mean item score, across all items
and treatments, was 2.14 (note: 2 5 ‘a little
true’, 3 5 ‘somewhat true’). Mean item scores
were slightly higher for positively worded
items (2.38) as compared to negatively worded
items (1.94).
Validation study—retrospective changes: A
total of 87 parents completed both a retrospective and current EESC scale. The retrospective
scale assessed the child’s most recent previously used ADHD medication, and thus was
not completed for patients who had not
changed medications. Of the 87 parents with
both scales completed, 44 were parents of
children who had switched from stimulants
(24 short acting, 20 long acting) to atomoxetine. Twenty four records were available for
children switching within the stimulant class:
11 from short to long acting, 7 switching
between long-acting medications, 5 between
short-acting medications, and 1 from long-acting
to a short-acting stimulant. Nineteen parents
provided data about switching from atomoxetine to stimulants.
Table 3 summarizes the changes from past to
current EESC within each medication pattern
group. Significant differences were noted in
mean retrospective EESC total scores, with
higher scores for patients with stimulants as
their past treatment as opposed to patients
with atomoxetine as their past treatment
(F[1,46] 5 6.7, p 5 0.013). All groups (those
switching from stimulants and those switching from atomoxetine) improved upon the
switch of medications, with larger improvements from patients switching from stimu-

lants. Those on stimulants in the past (whether
switching to atomoxetine or another stimulant) also had significant improvements using
each of the three EESC subscales.
Figure 2 presents the analysis of changes
from retrospective to current EESC scores
(total and subscales) for patients switching
from stimulants to atomoxetine versus patients switching from a stimulant to a different
stimulant. These two groups were compared
statistically because they had the largest
sample sizes and similar retrospective scores.
Patients switching from stimulants to atomoxetine had significantly greater improvements
in emotional expression compared to those
switching within the stimulant class (F[1,31]
5 8.1, p 5 0.008). Whereas those switching to
atomoxetine were found to have numerically
greater improvements on all three EESC subscales, the difference was driven primarily by
improvements in the Emotional Flatness subscale (F 5 13.8[1,33], p 5 0.001).
Clinical Trial—changes for atomoxetine- and
placebo-treated patients: In the double-blind
clinical trial, 136 patients randomized to atomoxetine and 65 patients randomized to
placebo had both a baseline and post-baseline
EESC scale completed. Table 4 presents the
summary statistics on baseline and change
scores for the EESC total as well as results of
the ANOVA assessment of differences between the atomoxetine and placebo groups.
Within-group mean changes over the 6-week
trial indicated small but statistically significant improvements for both atomoxetine and
placebo-treated patients. The analysis of treatment differences did not detect any statistically significant differences in change scores
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FIG. 2. Changes from retrospective to current EESC scores, validation study. Values reported are mean (SD).
STM_ATX–patients switched from a stimulant to atomoxetine; STM_STM 5 patients switched from a stimulant to
another stimulant. p Values are based on F tests from ANOVA with terms for demographics, site, treatment, retrospective score, and co-morbid diagnoses. F statistics (denominator df) were: Total, 8.1 (31); flat, 13.8 (33); emotion, 1.1
(36); and positive, 2.5 (32). EESC 5 Expression and Emotion scale for children; SD 5 standard deviation; ANOVA 5
analysis of variance.

between the atomoxetine and placebo groups
for the EESC total (F[1,190] 5 0.01, p 5 0.923)
and subscale scores.
In addition to evaluating mean changes, patients were also classified on the basis of their
changes relative to the SEM. This was done to
identify if there were subsets of patients in
either treatment group for whom emotional

expression changes were potentially problematic and that may be missed in a mean change
analysis. The percentages of patients with improvements of more than 1 SEM, no change
(improvement or worsening of , 1 SEM), and
worsening of at least 1 SEM were computed
for each treatment group. Table 5 summarizes these results. Once again, incidences of

TABLE 4. CHANGES FROM BASELINE TO END POINT IN EESC TOTAL SCORE: CLINICAL TRIAL.
Treatment
Total score
Atomoxetine
Placebo
Positive emotions
Atomoxetine
Placebo
Emotional flatness
Atomoxetine
Placebo
Emotional lability
Atomoxetine
Placebo

n

Baseline
mean (SD)

End point
mean (SD)

Change
Mean (SD)

F statistic
(denom df)

p value vs
placebo

136
65

63.6 (18.3)
68.2 (20.2)

60.4 (18.5)
63.6 (19.5)

23.1 (14.6)
24.6 (15.5)

0.01 (190)

0.923
—

139
65

31.4 (10.3)
34.0 (10.9)

31.2 (10.0)
32.9 (10.4)

20.2 (8.3)
21.2 (7.8)

0.00 (193)

0.973
—

137
66

17.7 (6.7)
18.5 (9.0)

16.5 (7.1)
16.3 (7.3)

21.2 (6.0)
22.1 (7.3)

0.40 (192)

0.528
—

138
68

14.6 (5.5)
15.7 (4.8)

12.7 (5.1)
14.1 (5.3)

21.9 (4.4)
21.6 (3.6)

1.59 (195)

0.209
—

EESC 5 Expression and Emotion scale for children; SD 5 Standard deviation; df 5 degrees of freedom; ANOVA 5
analysis of variance.
p values based on F tests from an ANOVA model on change from baseline to end-point scores with terms for baseline score, site, and treatment. Sample sizes vary across measures due to missing item scores.
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TABLE 5. ANALYSIS OF CATEGORICAL CHANGES IN EESC SCORES BY TREATMENT GROUP: CLINICAL TRIAL
Atomoxetine
(n 5 136)
categorical changea (%)
Same

Decrease

Increase

Same

Decrease

Chi-square
statistic

p value

8.8

62.5

28.7

12.3

63.1

24.6

0.80

0.669

13.7
8.8
13.8

67.6
64.2
44.9

18.7
27.0
41.3

12.3
10.6
8.8

64.6
68.2
57.4

23.1
21.2
33.8

0.54
0.86
3.01

0.762
0.649
0.222

Increase
Total score
Subscales
Positive
Flat
Emotional

Placebo
(n 5 65)
categorical changea (%)

EESC 5 Expression and Emotion scale for children; SEM 5 standard error of measurement; df 5 degrees of freedom.
a
Increase represents an increase (worsening) in scores of at least one SEM. Decrease represents improvement of at
least 1 SEM. Same represents absolute changes of less than 1 SEM. The SEM was determined by test–retest reliability
data for each subscale. Treatment differences in percentages were assessed using chi-square tests with 2 df.

worsening between the groups were similar,
and there were no statistically significance differences in any of the categories.

DISCUSSION
The EESC is potentially a useful clinical tool
for assessing changes in emotional and personality expression in children treated with
pharmacotherapy for ADHD. It goes beyond
the traditional focus on monitoring core symptoms of ADHD or commonly reported adverse
effects, such as changes in appetite or sleep.
Previous work has suggested that the EESC is
a reliable and valid tool with three factors:
Positive emotional expression, emotional flatness, and emotional lability. This analysis provided the initial use of the EESC to assess
medication group differences.
Three main findings regarding treatment
effects were suggested by the data. First, for
patients on stable treatment with their naturalistically selected medication (suggesting that
the medication was at least reasonably tolerated and effective), no treatment differences in
emotional expression were observed. This
finding included comparisons between atomoxetine and stimulants and between different types of stimulants. Second, the large
improvements from the retrospective to current EESC scores for patients changing medications suggest that emotional expression
may be improved in those patients experiencing

adverse emotional effects by selecting an alternative medication. Patients who switched from
stimulant treatments had greater improvements in emotional expression by switching
to atomoxetine than to another stimulant.
Third, the randomized double-blind placebocontrolled study suggested that atomoxetine
treatment did not dramatically improve emotional expression, nor did it negatively affect
emotional expression in children.
Limitations to this work include the nonrandomized nature of the treatment comparisons
from the validation study and the reliance
upon retrospective data to produce EESC
scores on past medication treatment. Potential
biases from using recall data include the possibility for scores to be influenced by the current
state of the parent, knowledge of resolution of
problems, and emphasis on salient events over
representative events (Gorin and Stone 2001;
Henker et al 2002). Given that no prospective
differences were found in responsiveness
using atomoxetine or placebo, there as yet is
no data prospectively demonstrating differential responsiveness to change on the EESC.
Thus, it is not absolutely clear whether atomoxetine has no effects on emotional responsiveness, or if EESC will be sensitive in
detecting changes in the kind of dysphoria
demonstrated by Whalen et al. (1989) with
MPH. Additionally, there is no placebocontrolled data yet available using the EESC
on stimulant treatment, or blinded comparator
studies. These data would be of interest to
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randomized patients needing to switch medications and to assess changes on the new medications. More data on responsiveness of the scale
and a greater understanding of the clinical
meaning of changes of various magnitudes also
will be valuable. Last, minor modifications to the
scale have been suggested and additional data
using the modified version should be collected.
Because this study represents the first look
at medication differences with the EESC, replication and extension to other child clinical and
nonclinical samples is needed. However, the
information gathered thus far indicates that
the EESC has the potential to provide clinically
valuable information regarding medication
effects on emotional expression in children
with ADHD.
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APPENDIX
EESC Version 1
Read each statement carefully and mark your response based on when your child is on his/her
current ADHD medication. Think about the past two weeks. There are no right or wrong answers.
On ADHD medication …
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.

My child does not talk enough
My child’s mood is flat
My child has sparkle in his/her personality
My child seems happy
My child gets upset easily
My child seems easy going
My child’s personality has blossomed
My child’s personality seems “dampened”
My child is outgoing
My child seems down
My child just doesn’t seem to be him/herself
My child stays to him/herself
My child is tearful
My child’s true personality comes through
My child is sluggish
My child zones out
My child lacks his/her spark
My child is irritable or cranky
My child shows a range of emotions
My child is enthusiastic towards life
My child is friendly
My child’s emotions seem flat
My child has mood swings
My child is spontaneous
My child is overly sensitive
My child is affectionate
My child is funny
My child is creative
My child is confident

Not at all
true

A little
true

Somewhat
true

Pretty much
true

Very much
true

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

Positive Subscale: items 3, 4, 6, 7, 9, 14, 20, 21, 24, 26, 27, 28, and 29.
Flat Subscale: items 1, 2, 8, 10, 11, 12, 15, 16, 17, and 22.
Emotional Lability Subscale: items 5, 13, 18, 23, and 25.
Note: The following revisions were proposed for Version 2.0 (Perwien et al., submitted):
The following items are deleted: items 19, 1, 2, 8, 10, 12, 15, 17, 22.
The following items are added: My child seems “blah” sometimes; My child isn't very social sometimes; My child
doesn't have much spunk sometimes; My child could care less what happens at times; My child seems too slowed
down sometimes; My child seems somewhat distant at times; My child looks somewhat zoned out at times; My
child's emotions appear a little flat at times.
Copyright © 2006 Eli Lilly and Company and University of Nebraska
For permission to use the scale free of charge, please contact Dr. Chris Kratochvil, Psychopharmacology Research
Center, University of Nebraska Medical Center: ckratoch@unmc.edu
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